Glythera


Glythera logo

Glythera is an emerging biotechnology company focused on developing antibody-based therapies for the treatment of cancer as well as broader based therapeutics.

Our main goal is to develop effective therapies to improve patients' lives. Our mission is to enable improved clinical regimes through creation of the next generation of safe, efficacious biotherapeutic products in the oncology and therapeutics markets. With substantial experience and expertise in bioprocessing and chemistry development, we have a proven track record of supporting programs centred on our core technologies - PermaLink and PermaCarb.

Contact Glythera via their website


News Archive

06/06/2017   Glythera launches £1m Innovate UK project to develop ADCs...more
04/04/2017   Glythera demonstrates improved activity and safety of PermaLink®-based ADCs...more

14/07/2016   Avacta and Glythera Announce Collaboration...more

27/07/2015   Glythera Led Consortium Wins Industrial Biotechnology Catalyst Funding...more

15/05/2014   ADC specialist Glythera names Ian Evetts as its new Commercial Director...more
25/04/2014   Glythera wins Innovation and Technology Award...more
26/02/2014   BioOutsource announces partnership with Glythera...more

21/02/2013   Glythera nominated for Bionow 2013 Biomedical Award...more

21/06/2012   Glythera relocates as part of a £2m funding round...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code